Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
COLL Collegium Pharmaceutical	$27.59 +2.7%	$28.34	$23.23 ▼ $42.29	$885.53M	0.76	441,599 shs	84,713 shs
ELVN Enliven Therapeutics	$18.79 -0.6%	$19.31	$13.30 ▼ $30.03	$920.79M	1.03	262,673 shs	32,677 shs
TSVT 2seventy bio	$4.99 -0.1%	$4.36	$2.29 ▼ $5.30	$260.91M	1.04	606,361 shs	126,616 shs
XFOR X4 Pharmaceuticals	$5.03 -5.7%	$8.45	$4.95 ▼ $37.50	$875.26M	0.58	92,117 shs	129,610 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
COLL Collegium Pharmaceutical	+0.30%	-0.15%	-9.56%	-17.98%	-26.22%
ELVN Enliven Therapeutics	+3.84%	+16.58%	-10.25%	-10.12%	+10.07%
TSVT 2seventy bio	+0.20%	0.00%	+0.81%	+99.60%	+17.27%
XFOR X4 Pharmaceuticals	+2,710.53%	-5.77%	-28.80%	-63.06%	-84.72%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
COLL Collegium Pharmaceutical	4.0301 of 5 stars	3.4	1.0	3.0	2.8	0.8	2.5
ELVN Enliven Therapeutics	2.2499 of 5 stars	3.6	0.0	0.0	2.8	4.2	0.0
TSVT 2seventy bio	1.7428 of 5 stars	2.1	2.0	0.0	2.5	2.5	1.3
XFOR X4 Pharmaceuticals	3.8262 of 5 stars	3.5	2.0	4.6	1.6	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
COLL Collegium Pharmaceutical	2.80	Moderate Buy	$43.60	58.03% Upside
ELVN Enliven Therapeutics	3.25	Buy	$40.33	114.68% Upside
TSVT 2seventy bio	2.29	Hold	$5.60	12.34% Upside
XFOR X4 Pharmaceuticals	3.00	Buy	$85.00	1,589.86% Upside

Current Analyst Ratings Breakdown

Latest TSVT, XFOR, ELVN, and COLL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/24/2025	TSVT 2seventy bio	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (E+)
4/9/2025	COLL Collegium Pharmaceutical	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$46.00 ➝ $46.00
4/8/2025	TSVT 2seventy bio	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (D-)
3/27/2025	XFOR X4 Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$45.00 ➝ $45.00
3/26/2025	XFOR X4 Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$90.00 ➝ $90.00
3/24/2025	COLL Collegium Pharmaceutical	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00 ➝ $50.00
3/22/2025	TSVT 2seventy bio	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (E+)
3/21/2025	ELVN Enliven Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$37.00 ➝ $39.00
3/14/2025	TSVT 2seventy bio	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$6.00 ➝ $5.00
3/11/2025	TSVT 2seventy bio	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
3/11/2025	TSVT 2seventy bio	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$9.00 ➝ $5.00

(Data available from 4/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
COLL Collegium Pharmaceutical	$631.45M	1.40	$10.00 per share	2.76	$5.99 per share	4.61
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	$5.97 per share	N/A
TSVT 2seventy bio	$37.86M	6.89	N/A	N/A	$5.04 per share	0.99
XFOR X4 Pharmaceuticals	$2.56M	341.62	N/A	N/A	$0.31 per share	16.23

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
COLL Collegium Pharmaceutical	$48.15M	$1.86	11.88	4.58	N/A	14.78%	104.67%	18.38%	5/8/2025 (Estimated)
ELVN Enliven Therapeutics	-$71.58M	-$1.89	N/A	N/A	N/A	N/A	-29.46%	-27.33%	5/13/2025 (Estimated)
TSVT 2seventy bio	-$217.57M	-$1.12	N/A	N/A	N/A	-207.25%	-53.65%	-23.67%	5/1/2025 (Estimated)
XFOR X4 Pharmaceuticals	-$101.17M	-$0.19	N/A	N/A	N/A	N/A	-236.19%	-75.14%	5/1/2025 (Estimated)

Latest TSVT, XFOR, ELVN, and COLL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	TSVT 2seventy bio	-$0.10	N/A	N/A	N/A	$13.96 million	N/A
5/13/2025	Q1 2025	ELVN Enliven Therapeutics	-$0.51	N/A	N/A	N/A	N/A	N/A
5/8/2025	Q1 2025	COLL Collegium Pharmaceutical	$1.50	N/A	N/A	N/A	$174.96 million	N/A
5/1/2025	Q1 2025	XFOR X4 Pharmaceuticals	-$0.14	N/A	N/A	N/A	$7.03 million	N/A
3/25/2025	Q4 2024	TSVT 2seventy bio	-$0.23	-$0.31	-$0.08	-$0.37	$12.84 million	$2.93 million
3/25/2025	Q4 2024	XFOR X4 Pharmaceuticals	-$5.10	-$6.00	-$0.90	-$0.20	$1.07 million	$1.43 million
3/13/2025	Q4 2024	ELVN Enliven Therapeutics	-$0.53	-$0.46	+$0.07	-$0.46	N/A	$0.03 million
2/27/2025	Q4 2024	COLL Collegium Pharmaceutical	$1.54	$1.63	+$0.09	$0.36	$179.68 million	$181.95 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
COLL Collegium Pharmaceutical	N/A	N/A	N/A	N/A	N/A
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	N/A
TSVT 2seventy bio	N/A	N/A	N/A	N/A	N/A
XFOR X4 Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
COLL Collegium Pharmaceutical	3.43	0.97	0.88
ELVN Enliven Therapeutics	N/A	17.44	17.44
TSVT 2seventy bio	N/A	4.95	4.95
XFOR X4 Pharmaceuticals	1.26	4.89	4.80

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
COLL Collegium Pharmaceutical	N/A
ELVN Enliven Therapeutics	95.08%
TSVT 2seventy bio	93.90%
XFOR X4 Pharmaceuticals	72.03%

Insider Ownership

Company	Insider Ownership
COLL Collegium Pharmaceutical	2.51%
ELVN Enliven Therapeutics	29.20%
TSVT 2seventy bio	7.20%
XFOR X4 Pharmaceuticals	1.62%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
COLL Collegium Pharmaceutical	210	32.13 million	30.97 million	Optionable
ELVN Enliven Therapeutics	50	49.00 million	34.59 million	Optionable
TSVT 2seventy bio	440	52.34 million	47.87 million	Optionable
XFOR X4 Pharmaceuticals	80	173.66 million	167.78 million	Optionable

TSVT, XFOR, ELVN, and COLL Headlines

Recent News About These Companies

X4 Pharmaceuticals To Implement 1-for-30 Reverse Stock Split On April 28

April 26 at 5:52 PM | nasdaq.com

X4 Pharmaceuticals trading halted, news pending

April 26 at 7:50 AM | markets.businessinsider.com

X4 Pharmaceuticals announces 1-for-30 reverse stock split

April 26 at 12:06 AM | markets.businessinsider.com

X4 Pharmaceuticals to conduct reverse stock split

April 24, 2025 | msn.com

X4 Pharmaceuticals to Report First-Quarter 2025 Financial Results and Host Conference Call and Webcast on May 1, 2025

April 24, 2025 | globenewswire.com

X4 Pharmaceuticals Announces Reverse Stock Split

April 24, 2025 | globenewswire.com

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 23, 2025 | globenewswire.com

Contrasting Pluri (NASDAQ:PLUR) & X4 Pharmaceuticals (NASDAQ:XFOR)

April 19, 2025 | americanbankingnews.com

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q4 2024 Earnings Call Transcript

March 29, 2025 | msn.com

XFOR: Full Enrollment of Phase 3 4WARD Trial Expected in 2H25…

March 27, 2025 | finance.yahoo.com

Breaking Down X4 Pharmaceuticals: 4 Analysts Share Their Views

March 27, 2025 | benzinga.com

X4 Pharmaceuticals reports Q4 EPS (20c) vs. (10c) last year

March 26, 2025 | markets.businessinsider.com

X4 Pharmaceuticals outlines expected 2026 Phase 3 trial data release for mavorixafor

March 25, 2025 | msn.com

X4 Pharmaceuticals, Inc. (XFOR) Q4 2024 Earnings Call Transcript

March 25, 2025 | seekingalpha.com

X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

March 25, 2025 | globenewswire.com

X4 Pharmaceuticals Q4 2024 Earnings Preview

March 24, 2025 | msn.com

X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2024 Financial Results and Host a Conference Call and Webcast on March 25, 2025

March 11, 2025 | globenewswire.com

X4 and taiba rare announce distribution agreement for Xolremdi

February 19, 2025 | markets.businessinsider.com

X4 Pharmaceuticals and taiba rare Announce Exclusive Agreement for the Distribution and Commercialization of XOLREMDI® (mavorixafor) in WHIM Syndrome in Select Middle East Countries

February 19, 2025 | globenewswire.com

X4 pharmaceuticals chief commercial officer Mark Baldry acquires $19,251 in stock

February 14, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TSVT, XFOR, ELVN, and COLL Company Descriptions

Collegium Pharmaceutical NASDAQ:COLL

$27.59 +0.72 (+2.68%)

As of 12:40 PM Eastern

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Enliven Therapeutics NASDAQ:ELVN

$18.79 -0.12 (-0.65%)

As of 12:41 PM Eastern

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

2seventy bio NASDAQ:TSVT

$4.99 -0.01 (-0.10%)

As of 12:40 PM Eastern

2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.

X4 Pharmaceuticals NASDAQ:XFOR

$5.03 -0.31 (-5.72%)

As of 12:39 PM Eastern

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time